Thursday, June 11

Browsing: SCREESCO

Research

Colonoscopy and fecal immunochemical testing versus usual care in diagnostic colorectal cancer screening: the SCREESCO randomized controlled trial

By NewsCancerFebruary 22, 20260

This study has trial number NCT02078804 and is registered with ClinicalTrials.gov at https://clinicaltrials.gov/study/NCT02078804.Eligibility criteriaWe performed an individual RCT with a…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor–stromal signaling

76 Real-World Safety of Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Insights From US Community Oncology Practices

75 Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Real-World Treatment Patterns and Outcomes From Community Oncology Settings

Browsing: SCREESCO

Colonoscopy and fecal immunochemical testing versus usual care in diagnostic colorectal cancer screening: the SCREESCO randomized controlled trial

CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor–stromal signaling

76 Real-World Safety of Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Insights From US Community Oncology Practices

75 Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Real-World Treatment Patterns and Outcomes From Community Oncology Settings

Combination of paricalcitol with chemotherapy shows promise in phase 1 study of metastatic pancreatic cancer

CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor–stromal signaling

76 Real-World Safety of Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Insights From US Community Oncology Practices

75 Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Real-World Treatment Patterns and Outcomes From Community Oncology Settings

Combination of paricalcitol with chemotherapy shows promise in phase 1 study of metastatic pancreatic cancer

Latest Post

CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor–stromal signaling

76 Real-World Safety of Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Insights From US Community Oncology Practices

75 Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Real-World Treatment Patterns and Outcomes From Community Oncology Settings

Subscribe to Updates

What's Hot

Browsing: SCREESCO